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EDITORIALCathelicidins: A Novel Therapy for the Treatment
of Intestinal Fibrosis?ntestinal ﬁbrosis is an important complication ofICrohn’s disease (CD), often leading to stricture for-
mation that progressively could induce intestinal obstruc-
tion. The excessive presence of ﬁbrous connective tissue
increases the thickness of the bowel wall, reducing the
elasticity and the function over the affected area.
Although considerable advances have been made in the
understanding of the molecular mechanisms underlying the
ﬁbrotic process, to date there are neither speciﬁc therapies
nor speciﬁc markers that might be useful as accurate pre-
dictors or diagnostic tools for prevention or treatment.
Surgical removal is the only means of eliminating the
ﬁbrostenosing and obstructing strictures, which can be
recurrent in the same patient, signiﬁcantly inﬂuencing the
quality of life. Anti-inﬂammatory therapies are not efﬁcient
in resolving ﬁbrosis because 20% of CD patients treated
with biologics still develop strictures and associated com-
plications. This shows that simple removal of the inﬂam-
matory trigger is not sufﬁcient to reverse ﬁbrosis.
Nevertheless, several currently used drugs, including corti-
costeroids, azathioprine, and anti–tumor necrosis factor
(TNF) biologics, can prevent postoperative CD recurrence.
These data show that despite the incompletely deﬁned
pathogenesis of strictures in CD that remain unclear,
inﬂammation is an essential trigger that initiates ﬁbrosis.
Transforming growth factor-b (TGF-b) is the most
prominent proﬁbrogenic factor capable of inducing extra-
cellular matrix deposition, metalloproteinase inhibition, andFigure 1. LL-37 involvement in intestinal ﬁbrotic process. P
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receptors are up-regulated in CD strictures. Unfortunately,
in a study of patients with systemic sclerosis, an anti–TGF-
b1 monoclonal antibody was unable to reduce ﬁbrosis.1
Although mechanisms of ﬁbrosis may differ between sys-
temic sclerosis and CD, this reduces any hope that anti–TGF-
b1 biologics will be of beneﬁt to CD patients. Furthermore,
TGF-b is a pleiotropic cytokine with immunomodulatory
functions that are critical to maintenance of intestinal ho-
meostasis. Thus, despite its role as a proﬁbrogenic factor,
blockade of the TGF-b/TGF-b–receptor axis is unlikely to be
successful as a therapeutic approach in structuring CD.
Recent work in extraintestinal organs has elucidated the
involvement of cathelicidins, antimicrobial cationic peptides,
in ﬁbrosis. Cathelicidins are synthesized and secreted in
large amounts by tissues exposed to bacteria, including
gastrointestinal, genitourinary, respiratory tract, and skin.
Remarkably, LL37, the cleaved form of the human cath-
elicidin hCAP18, is able to decrease TGF-b–induced collagen
synthesis in human keloid ﬁbroblasts by a mechanisms
that includes activation of the extracellular signal-regulated
kinase (ERK) pathway.2
In this issue of Cellular and Molecular Gastroenterology
and Hepatology, Yoo et al3 aimed to determine if cath-
elicidins also might be able to limit intestinal ﬁbrosis. This is
an attractive hypothesis because LL-37 is expressed by
many cell types, including intestinal epithelial cells and
inﬁltrating neutrophils. By using 2 preclinical models ofroﬁbrotic factors such as TGF-b promote collagen (Col1a2)
nd matrix metalloproteinase (MMP) inhibition, both of which
icrobial properties, LL-37 ameliorates intestinal inﬂammation,
operties via ERK-mediated signaling that is independent of
January 2015 Editorial 3intestinal ﬁbrosis, Yoo et al3 showed that LL-37 not only
ameliorates intestinal inﬂammation, as indicated by reduced
TNF-a expression, but also prevents ﬁbrosis. Results were
similar with either intracolonic administration of recombi-
nant LL-37 or virally mediated LL-37 expression. LL-37 also
inhibited TGF-b–induced collagen production by primary CD
intestinal ﬁbroblasts in vitro. However, in vivo LL-37 ther-
apy did not affect TGF-b1 expression, suggesting that its
antiﬁbrotic properties are not a result of the modiﬁcation
of the TGF-b/TGF-b receptor axis. Furthermore, LL-
37–mediated inhibition of collagen production was reversed
by ERK inhibitors, implying that the same ERK signaling
pathway described in dermal ﬁbroblasts is involved in the
regulation of intestinal ﬁbroblasts and ﬁbrosis (Figure 1).
It is widely documented that CD patients have impaired
production of antimicrobial agents, including LL-37. How-
ever, it is not clear if this reduced LL-37 production is
involved in the development of intestinal ﬁbrosis. For
example, despite impaired antibacterial defense, cathelicidin-
deﬁcient mice developed inﬂammation and ﬁbrosis that was
comparable with wild-type mice, indicating no increased
predisposition to intestinal ﬁbrosis in the absence of LL-37.
However, exogenous LL-37 administration suppressed
collagen synthesis and colonic TNF-a production in
cathelicidin-deﬁcient mice. Results were similar in amodel of
ﬁbrosis inﬂammation-independent, suggesting that the anti-
ﬁbrotic activity of LL-37 is not linked to its anti-inﬂammatory
properties.
Notwithstanding these exciting results, further studies
are needed to better understand the mechanisms by which
cathelicidin limits intestinal ﬁbrosis because the data indi-
cate that these effects were independent of putative cath-
elicidin receptors. Similarly, it will be interesting to assess
the effects of LL-37 on the matrix metalloproteinase
expression and activity. Furthermore, many questions
related to the delivery route, stability, and effects oflong-term LL-37 treatment on intestinal homeostasis,
including the microbiome, remain to be addressed.
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